RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Marcia Cruz-Correa to Clinical Trials, Phase III as Topic

Back to Details
This is a "connection" page, showing publications Marcia Cruz-Correa has written about Clinical Trials, Phase III as Topic.
Marcia Cruz-Correa
Connection Strength
0.058
Clinical Trials, Phase III as Topic
  1. Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression?=?1%: A Retrospective Analysis of RATIONALE-305. Adv Ther. 2025 May; 42(5):2248-2268.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support